Adverse effects of multi-drug therapy in leprosy, a two years' experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh state (Bastar, Jagdalpur)

Leprosy Review

Volumn 82, Issue 1, 2011, Pages 17-24

  Singh, Harminder ^a   Nel, Bithika ^a   Dey, Vivek ^a   Tiwari, Pawan ^a   Dulhani, Naveen ^a  

^a Govt Medical College   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; DAPSONE; RIFAMPICIN;

ABDOMINAL DISEASE; ADOLESCENT; ADULT; ARTICLE; BODY MASS; CHILD; CONTROLLED STUDY; CORRELATION COEFFICIENT; DAPSONE SYNDROME; DESCRIPTIVE RESEARCH; DIZZINESS; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ETHNIC GROUP; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HEMATEMESIS; HEMOLYTIC ANEMIA; HUMAN; INDIA; INFANT; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; MEDICAL RECORD; METHEMOGLOBINEMIA; MULTIBACILLARY LEPROSY; PAUCIBACILLARY LEPROSY; PROSPECTIVE STUDY; RETICULOCYTE; SIDE EFFECT; SKIN MANIFESTATION; SKIN TOXICITY; TERTIARY HEALTH CARE; TREATMENT DURATION;

ADOLESCENT; ADULT; BODY MASS INDEX; CLOFAZIMINE; DAPSONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDIA; LEPROSTATIC AGENTS; LEPROSY; MALE; PROSPECTIVE STUDIES; RIFAMPIN; RISK FACTORS;

EID: 79957484580     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. State-wise distribution of registered leprosy cases, DGHS, Govt. of India, nlep.nic.in/pdf/AnnualReport2007_08, annexure-II.
2. Morel CM. Foreword. Multi drug therapy against leprosy. Development and implementation over the past 25 years. World Health Organization, Geneva, 2004, pp. vii.
3. Norman G, Joseph G, Richard J. Relapses in multi bacillary patients treated with multi-drug therapy until smear negativity: Findings after twenty years. Int J Lepr Other Mycobact Dis, 2004; 72: 1-7.
4. William AP. Chemotherapy of tuberculosis, mycobacterium avium complex Disease, and Leprosy. In: Laurence LB, John SL, Keith L. Parker (eds). Goodman Gilman's the pharmacological basis of therapeutics, 11th ed. McGraw-Hill: medical publishing division, 2006, pp. 1219-1220.
5. Girling DJ. Adverse reactions to rifampicin in anti-tuberculosis regimens. J Anti Microb Chemo Ther, 1977; 3: 115-132.
6. WHO Expert Committee on Leprosy. Seventh report. WHO, Technical Report Series 874, 1998.
7. Brasil MTLRF, Opromolla DVA, Marzliak MLC et al. Results of a surveillance system for adverse effects in leprosy's WHO/MDT. Int J Lepr Other Mycobact Dis, 1996; 64: 97-104.
8. Goulart IMB, Arbex GL, Carneiro MH et al. Adverse effects of multi drug therapy in leprosy patients: a five-year survey at a Health Centre of the Federal University of Uberlandia. Rev Soc Bras Med Trop, 2002; 35: 453-460.
9. Deps PD, Nasser S, Guerra P et al. Adverse effects from multi-drug therapy in leprosy: a Brazilian study. Lepr Rev, 2007; 78: 216-222.
10. Pandey B, Shrestha K, Lewis J et al. Mortality due to dapsone hypersensitivity syndrome complicating multi-drug therapy for leprosy in Nepal. Trop Doct, 2007; 37: 162-163.
11. WHO Recommended surveillance Standards 2nd edition, Oct 1999, page-73. WHO_CDS_CSR_ISR_99.2.pdf.
12. WHO (1988). Techn. Rep. Ser., No. 768.
13. WHO. WHO Essential Medicines Library http://apps.who.int/emlib/MedicineDisplay.aspx?Language=EN&MedIDName=79%40clofazimine. Accessed in 2009.
14. WHO. The Final Push Strategy to Eliminate Leprosy as a Public Health Problem. 2003. http://whqlibdoc.who.int/hq/2003/WHO_CDS_CPE_CEE_2003.37.pdf.
15. Mahmood K, Hussain A, Jairamani KL et al. Hepatotoxicity with Antituberculosis Drugs: the risk factors. Pak J Med Sci, 2007; 23: 33-38.
16. WHO expert consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet, 2004; 363: 157-163.